Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: a randomized double-blind placebo-controlled study
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Effective prophylactic therapies have not been established for hepatocellular carcinoma recurrence. Peretinoin represents one novel option for patients with hepatitis C virus-related hepatocellular carcinoma (HCV-HCC), and it was tested in a multicenter, randomized, double-blind, placebo-controlled study. METHODS: Patients with curative therapy were assigned to one of the following regimens: peretinoin 600, 300 mg/day, or placebo for up to 96 weeks. The primary outcome was recurrence-free survival (RFS). RESULTS: Of the 401 patients initially enrolled, 377 patients were analyzed for efficacy. The RFS rates in the 600-mg group, the 300-mg group, and the placebo group were 71.9, 63.6, and 66.0 % at 1 year, and 43.7, 24.9, and 29.3 % at 3 years, respectively. The primary comparison of peretinoin (300 and 600-mg) with placebo was not significant (P = 0.434). The dose-response relationship based on the hypothesis that "efficacy begins to increase at 600 mg/day" was significant (P = 0.023, multiplicity-adjusted P = 0.048). The hazard ratios for RFS in the 600-mg group vs. the placebo group were 0.73 [95 % confidence interval (CI) 0.51-1.03] for the entire study period and 0.27 (95 % CI 0.07-0.96) after 2 years of the randomization. Common adverse events included ascites, increased blood pressure, headache, presence of urine albumin, and increased transaminases. CONCLUSIONS: Although the superiority of peretinoin to placebo could not be validated, 600 mg/day was shown to be the optimal dose, and treatment may possibly reduce the recurrence of HCV-HCC, particularly after 2 years. The efficacy and safety of peretinoin 600 mg/day should continue to be evaluated in further studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 21,293
Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification
Llovet, J., Brú, C., & Bruix, J. (1999) · Seminars in Liver Disease · doi:10.1055/s-2007-1007122 · Cited by 3,805 · cited 1×
“Curative resection or ablation is indicated for early HCC [5–7].”
BackgroundLlovet, J. M., Burroughs, A., & Bruix, J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14964-1 · Cited by 3,608
The Prevalence of Hepatitis C Virus Infection in the United States, 1999 through 2002
Armstrong, G. L., Wasley, A., Simard, E. P., McQuillan, G. M., Kuhnert, W. L., & Alter, M. J. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-10-200605160-00004 · Cited by 1,955
Resampling-Based Multiple Testing: Examples and Methods for p-Value Adjustment.
Martin, M. A., Westfall, P. H., & Young, S. S. (1994) · Biometrics · doi:10.2307/2533464 · Cited by 1,699
Altekruse, S. F., McGlynn, K. A., & Reichman, M. E. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.7753 · Cited by 1,694
Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma
Llovet, J. M., Di Bisceglie, A. M., Bruix, J., Kramer, B. S., Lencioni, R., Zhu, A. X., Sherman, M., Schwartz, M., Lotze, M., Talwalkar, J., et al. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djn134 · Cited by 1,653 · cited 1×
“The guidelines for clinical studies of HCC recommend inclusion of patients with Child-Pugh A in clinical trials because death from cirrhosis in patients with Child-Pugh B or C could mask the efficacy of treatment [28].”
BackgroundImamura, H., Matsuyama, Y., Tanaka, E., Ohkubo, T., Hasegawa, K., Miyagawa, S., Sugawara, Y., Minagawa, M., Takayama, T., Kawasaki, S., et al. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00360-4 · Cited by 1,589 · cited 3×
“However, multicentric de novo carcinogenesis is the common cause of recurrence after 2 years [11, 12].”
BackgroundSelf-citation[Gastric adenocarcinoma and kidney transplantation].
Barrio, J., García-Bengoechea, M., Emparanza, J. I., & Arenas, J. I. (1998) · PubMed · Cited by 1,132
The Continuing Increase in the Incidence of Hepatocellular Carcinoma in the United States: An Update
El-Serag, H. B., Davila, J. A., Petersen, N. J., & McGlynn, K. A. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-10-200311180-00009 · Cited by 943 · cited 1×
“The incidence of HCC has been rising due to an increase in hepatitis-C virus infections [2–4].”
BackgroundResampling-Based Multiple Testing: Examples and Methods for p-Value Adjustment
Chaubey, Y. P., Westfall, P. H., & Young, S. S. (1993) · Technometrics · doi:10.2307/1270279 · Cited by 920
Resection and Liver Transplantation for Hepatocellular Carcinoma
Llovet, J. M., Schwartz, M., & Mazzaferro, V. (2005) · Seminars in Liver Disease · doi:10.1055/s-2005-871198 · Cited by 879 · cited 1×
“However, the 3-year recurrence rate after curative treatment in the general population is 50 % [8, 9].”
BackgroundTables of the number of patients required in clinical trials using the logrank test
Freedman, L. S. (1982) · Statistics in Medicine · doi:10.1002/sim.4780010204 · Cited by 718 · cited 1×
“placebo] was calculated using Freedman’s formula [25].”
Muto, Y., Moriwaki, H., Ninomiya, M., Adachi, S., Saito, A., Takasaki, K. T., Tanaka, T., Tsurumi, K., Okuno, M., Tomita, E., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199606133342402 · Cited by 668
Self-citationCastells, A., Bruix, J., Bru, C., Fuster, J., Vilana, R., Navasa, M., Ayuso, C., Boix, L., Visa, J., & Rodés, J. (1993) · Hepatology · doi:10.1002/hep.1840180517 · Cited by 368 · cited 1×
“However, the 3-year recurrence rate after curative treatment in the general population is 50 % [8, 9].”
BackgroundMazzaferro, V., Romito, R., Schiavo, M., Mariani, L., Camerini, T., Bhoori, S., Capussotti, L., Calise, F., Pellicci, R., Belli, G., et al. (2006) · Hepatology · doi:10.1002/hep.21415 · Cited by 367 · cited 2×
“However, multicentric de novo carcinogenesis is the common cause of recurrence after 2 years [11, 12].”
BackgroundChemoprevention of cancer with retinoids
Peck, G. L. (1981) · Gynecologic Oncology · doi:10.1016/0090-8258(81)90086-x · Cited by 365 · cited 1×
“The concept of chemoprevention using retinoids has been proposed as a means to delay or prevent recurrence after treatment of HCC [16].”
BackgroundMuto, Y., Moriwaki, H., & Shiratori, Y. (1998) · Digestion · doi:10.1159/000051435 · Cited by 315
Self-citationChemoprevention of cancer with retinoids.
Sporn, M., & Newton, D. L. (1979) · PubMed · Cited by 286
Shiratori, Y., Shiina, S., Teratani, T., Imamura, M., Obi, S., Sato, S., Koike, Y., Yoshida, H., & Omata, M. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-4-200302180-00008 · Cited by 274 · cited 1×
“Furthermore, the recurrence rate is [70 % in hepatitis C virus-positive patients [10].”
BackgroundPrevention of Second Primary Tumors by an Acyclic Retinoid in Patients with Hepatocellular Carcinoma
Muto, Y., Moriwaki, H., & Saito, A. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904013401315 · Cited by 265
Self-citationKudo, M., & Okanoue, T. (2007) · Oncology · doi:10.1159/000111702 · Cited by 196
Self-citationIwasaki, Y., Ikeda, H., Araki, Y., Osawa, T., Kita, K., Ando, M., Shimoe, T., Takaguchi, K., Hashimoto, N., Kobatake, T., et al. (2006) · Hepatology · doi:10.1002/hep.20984 · Cited by 170 · cited 1×
“While safety issues prevent the use of interferon in elderly patients [29, 30], this study indicated that peretinoin was well tolerated by such elderly patients.”
BackgroundBreitenstein, S., Dimitroulis, D., Petrowsky, H., Puhan, M. A., Müllhaupt, B., & Clavien, P.-A. (2009) · British Journal of Surgery · doi:10.1002/bjs.6731 · Cited by 150 · cited 1×
“A previous study revealed that 25 % of adverse reactions to interferon were severe, resulting in treatment discontinuation or dose reduction [13].”
MethodNeoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma
Samuel, M., Chow, P. K.-H., Chan Shih-Yen, E., Machin, D., & Soo, K.-C. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001199.pub2 · Cited by 145 · cited 2×
“Most importantly, no effective approach has been established to prevent HCC recurrence [13–15].”
BackgroundSuzui, M., Masuda, M., Lim, J. T. E., Albanese, C., Pestell, R. G., & Weinstein, I. B. (2002) · PubMed · Cited by 130
Oral retinoids-efficacy and toxicity in psoriasis
Gollnick, H. P. M. (1996) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1996.tb15661.x · Cited by 106 · cited 2×
“Adverse reactions associated with other retinoids [26] (e.”
BackgroundMethodMathurin, P., Raynard, B., Dharancy, S., Kirzin, S., Fallik, D., Pruvot, F., Roumilhac, D., Canva, V., Paris, J.-C., Chaput, J., et al. (2003) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2003.01580.x · Cited by 101 · cited 2×
“Most importantly, no effective approach has been established to prevent HCC recurrence [13–15].”
BackgroundInduction of Apoptosis by Acyclic Retinoid in the Human Hepatoma-Derived Cell Line, HuH-7
Nakamura, N., Shidoji, Y., Yamada, Y., Hatakeyama, H., Moriwaki, H., & Muto, Y. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.1199 · Cited by 99 · cited 1×
“Peretinoin is known to suppress tumor growth in the human liver by inducing apoptosis and differentiation of liver cancer cells [18, 19]; it also acts by increasing p21 protein levels and reducing cyclin D1 levels to inhibit proliferation of these cells [20].”
BackgroundSelf-citationRetinoid Agonist Activities of Synthetic Geranyl Geranoic Acid Derivatives
Araki, H., Shidoji, Y., Yamada, Y., Moriwaki, H., & Muto, Y. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.1471 · Cited by 96 · cited 1×
“Peretinoin [(2E,4E,6E,10E)3,7,11,15-Tetramethylhexadeca-2,4,6,10,14-pentaenoic acid] is a synthetic retinoid with a retinoic acid receptor and retinoid X receptor agonist activity [17].”
BackgroundSelf-citationElderly Patients Are at Greater Risk of Cytopenia During Antiviral Therapy for Hepatitis C
Nudo, C. G., Wong, P. Y. N., Hilzenrat, N., & Deschênes, M. (2006) · Canadian Journal of Gastroenterology · doi:10.1155/2006/357259 · Cited by 56 · cited 1×
“While safety issues prevent the use of interferon in elderly patients [29, 30], this study indicated that peretinoin was well tolerated by such elderly patients.”
BackgroundYasuda, I., Shiratori, Y., Adachi, S., Obora, A., Takemura, M., Okuno, M., Shidoji, Y., Seishima, M., Muto, Y., & Moriwaki, H. (2002) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00044-2 · Cited by 56 · cited 1×
“Peretinoin is known to suppress tumor growth in the human liver by inducing apoptosis and differentiation of liver cancer cells [18, 19]; it also acts by increasing p21 protein levels and reducing cyclin D1 levels to inhibit proliferation of these cells [20].”
BackgroundSelf-citationHonda, M., Yamashita, T., Yamashita, T., Arai, K., Sakai, Y., Sakai, A., Nakamura, M., Mizukoshi, E., & Kaneko, S. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-191 · Cited by 33 · cited 1×
“However, there was little change or no change in expression of these genes with treatment at 300 mg/day [27].”
BackgroundSelf-citationPhase I and pharmacokinetic clinical trial of oral administration of the acyclic retinoid NIK‐333
Okusaka, T., Ueno, H., Ikeda, M., & Morizane, C. (2011) · Hepatology Research · doi:10.1111/j.1872-034x.2011.00800.x · Cited by 25
Self-citation
Cited by
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
“regulatory agreement, incorporated a composite endpoint of recurrence-free survival, where around 90% of events were recurrences.(394,628) Regulatory agencies endorse this composite”
BackgroundAASLD guidelines for the treatment of hepatocellular carcinoma
Heimbach, J. K., Kulik, L. M., Finn, R. S., Sirlin, C. B., Abecassis, M. M., Roberts, L. R., Zhu, A. X., Murad, M. H., & Marrero, J. A. (2018) · Hepatology · doi:10.1002/hep.29086 · Cited by 4,070
“Early studies with the adjuvant use of acyclic retinoids were promising,((50)) with a decrease in the development of secondary tumors, but larger studies did not confirm a benefit.((51)) The lack of proven active agents in advanced disease has hampered the development of agents targeting early-stage disease.”
Omata, M., Cheng, A.-L., Kokudo, N., Kudo, M., Lee, J. M., Jia, J., Tateishi, R., Han, K.-H., Chawla, Y. K., Shiina, S., et al. (2017) · Hepatology International · doi:10.1007/s12072-017-9799-9 · Cited by 2,171
“However, in a large-scale RCT, the superiority of acyclic retinoid over placebo could not be validated, 600 mg per day was shown to be the optimal dose, and treatment may possibly reduce the recurrence of HCV-related HCC, particularly after 2 years [211].”
BackgroundSelf-citationHepatic stellate cells as key target in liver fibrosis
Higashi, T., Friedman, S. L., & Hoshida, Y. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.05.007 · Cited by 1,485
Bruix, J., Takayama, T., Mazzaferro, V., Chau, G.-Y., Yang, J., Kudo, M., Cai, J., Poon, R. T., Han, K.-H., Tak, W. Y., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00198-9 · Cited by 1,120
Self-citation
Metadata
- Authors
- Peretinoin Study Group, Okita, K., Izumi, N., Matsui, O., Tanaka, K., Kaneko, S., Moriwaki, H., Ikeda, K., Osaki, Y., Numata, K., Nakachi, K., Kokudo, N., Imanaka, K., Nishiguchi, S., Okusaka, T., Nishigaki, Y., Shiomi, S., Kudo, M., Ido, K., Karino, Y., Hayashi, N., Ohashi, Y., Makuuchi, M., & Kumada, H.
- Affiliations
- Musashino Red Cross Hospital (JP)
- Kanazawa University Hospital (JP)
- Yokohama City University Medical Center (JP)
- Gifu University Hospital (JP)
- Osaka Red Cross Hospital (JP)
- University of Tokyo Hospital (JP)
- Osaka International Cancer Institute (JP)
- Hyogo Medical University Hospital (JP)
- Gifu Municipal Hospital (JP)
- Kindai University Hospital (JP)
- Sapporo Kosei General Hospital (JP)
- Kansai Rosai Hospital (JP)
- Japanese Red Cross Medical Center (JP)
- Japanese Red Cross Society, Japan (JP)
- Toranomon Hospital (JP)
- Corresponding author
- Okita, Kiwamu
- ORCID
- Venue
- Journal of Gastroenterology
- Published
- 2014-04-13
- Volume
- 50
- Issue
- 2
- Pages
- 191-202
- ISSN
- 0944-1174 (ISSN-L)
- 1435-5922
- PMC
- PMC4318984
- OpenAlex
- W2022144305
- Cited by
- 90
- References
- 34
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 7 · 2023: 9 · 2022: 5 · 2021: 9 · 2020: 11 · 2019: 7 · 2018: 9 · 2017: 8 · 2016: 4 · 2015: 9 · 2014: 7
- FWCI
- 5.21
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Gastroenterology (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- Taiho Pharmaceutical
- Nihon Medi-Physics
- Kowa Company
- Boehringer Ingelheim Japan
- Nippon Shinyaku
- Dainippon Sumitomo Pharma
- Eisai
- Kyowa Hakko Kirin
- Astellas Pharma
- Otsuka Pharmaceutical
- Ajinomoto Pharmaceuticals
- Mitsubishi Tanabe Pharma Corporation
- Ono Pharmaceutical
- Chugai Pharmaceutical
- Japan Society for the Promotion of Science (221S0001)
- Topics
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Hepatology › Hepatitis C virus research
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- recurrent hepatocellular carcinoma, recurrence-free survival, adjuvant therapy, dose-response relationship, curative treatment, hepatoprotection, adverse events
- MeSH terms
- Aged, Dose-Response Relationship, Drug, Double-Blind Method, Female, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Male, Middle Aged, Neoplasm Recurrence, Local, Retinoids, Anticarcinogenic Agents, Treatment Outcome, Disease-Free Survival, Hepatitis C, Chronic, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.